Top 50 Biotechnology Startup Investors in December 2024
A list of 50 angel investors and VC (Venture Capital) funds that invest in Biotechnology startups. We rank investors based on the number of investments they made in Biotechnology companies. This investor list updates every month.Top 50 Biotechnology Startup Investors in December 2024
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, China, United Kingdom
Portfolio highlights
- Metsera — Metsera operates as a clinical-stage biopharmaceutical company.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, China, Israel
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
- Lomond Therapeutics — Targeting escape mutations in hematological cancers with first and best in class medicines.
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Canada, France
Portfolio highlights
- Jupiter BioVentures — Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.
- Valora Therapeutics — Valora Therapeutics is a biotechnology company that provides engineering of chimeric antibodies .
- Autoimmunity BioSolutions — ABS is developing a next-generation, immuno-corrective therapy to restore normal immune function in a genetically-defined subpopulation of autoimmune disease patients.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- France, United States, United Kingdom
Portfolio highlights
- deepc — The Radiology AI Platform - Your effortless access to AI
- Genespire — Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
- Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series A, Series B, Series C
- United States, Denmark, United Kingdom
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Nuvig Therapeutics — Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmunediseases.
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- 858 Therapeutics — 858 Therapeutics is a stealth company specializing in the area of healthcare services, pharmaceutical, and biotechnology. The company was founded in 2019 and is headquartered in San Diego, California, USA.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Pep2Tango Therapeutics — Pep2Tango Therapeutics is a biotechnology company that offers superior unimolecular multi-receptor drugs for obesity and related disorders.
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series B, Series A, Series C
- United States, India, China
Portfolio highlights
- Sana — Sana is an AI company building the next generation of knowledge tools. Designed and engineered in Stockholm, Sweden.
- Fastino — Fastino provides enterprise AI developers with high-performance, task-optimized language models built to scale.
- Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series A, Series B, Series C
- United States, United Kingdom, China
Portfolio highlights
- Teleo — Teleo is revolutionizing material moving industries by turning heavy equipment into supervised autonomous machines.
- Zenflow — Zenflow was founded in 2014 by a team of Stanford University Biodesign Fellows working in collaboration with top global urologists. After witnessing patients' frustration with existing treatment options, the founders made it their mission to find a better solution to this large unmet clinical need.
- Lighthouse — Lighthouse is a commercial platform for the travel & hospitality industry. The company transforms complexity into confidence by providing actionable market insights, business intelligence, and pricing tools that maximize revenue growth. Lighthouse was previously known as OTA Insight.
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
Khosla Ventures invests in companies that are bold, early and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Headquartered in Menlo Park, Calif., Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech,digital health, medtech and diagnostics, therapeutics and frontier technology.
Show more
Investment focus
- Software, Health Care, Artificial Intelligence
- Series A, Series B, Seed
- United States, India, United Kingdom
Portfolio highlights
- Moonvalley — The imagination research company building ML video and image models that captivate.
- Vitara Biomedical — Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care.
- Outsmart Education — Join the waitlist and see why higher education will never again be the same.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series C, Series A
- United States, United Kingdom, Canada
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Metsera — Metsera operates as a clinical-stage biopharmaceutical company.
- Synapticure — The era of personalized care is finally coming to ALS. Synapticure will give all ALS patients access to the best care while fueling the advancement of personalized treatments for every type of ALS.
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series B, Series A, Series C
- United States, Singapore, Ireland
Portfolio highlights
- TRex Bio — TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
- Sunbird Bio — Sunbird Bio, a biotech company, is developing protein-based diagnostic tests that empower diagnosis and treatment of Alzheimer's disease, neurological disorders, and early-stage cancer.
- Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries.
5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- RareCyte — Rarecyte provides precision medicine solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics.
- TMRW Life Sciences — TMRW helps patients and clinics safely store their eggs and embryos
- Tectonic Therapeutic — Tectonic and AVROBIO have completed their anticipated merger.Please follow this link to our press release for additional information.
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more
Investment focus
- Health Care, Biotechnology, Medical
- Series B, Series A, Series C
- China, United States, Hong Kong
Portfolio highlights
- XellSmart — Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.
- LongBio Pharma — LongBio Pharma is a biotech company that treats patients with an emphasis on complement and allergy diseases.
- Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Powering Breakthroughs in Life Sciences
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
- Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
- Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more
Investment focus
- Health Care, Medical, Medical Device
- Seed, Pre-Seed, Convertible Note
- United States, Argentina, United Kingdom
Portfolio highlights
- Rantizo — Fly more acres, deliver better service. The equipment, tools, and expertise you need to be the grower's first call for drone spray services.
- iYOTAH Solutions — Take your dairy operation to the next level. Our state of the art platform helps you save time, increase efficiencies and profits and unlock new opportunities.
- Glanris — Glanris developed a completely green, non-toxic, filtration media for water purification from an agriculture by-product. This agricultural product is grown around the world, is plentiful, and can be used locally to ensure clean drinking water in developing countries. It also gives local farmers a significant additional income source for a productthat today they are throwing away.This media has been independently tested over the last two years of development and is ready for production.
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Marea Therapeutics — Marea Therapeutics is a clinical-stage biotechnology firm that uses the most recent advancements in human genetics to create first-in-class, next-generation medications for cardiometabolic illnesses.
- Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
- Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, United Kingdom, Switzerland
Portfolio highlights
- Enara Bio — Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-relatedDNA sequences.
- IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
- Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
- Exsilio Therapeutics — Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells.
- Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.
Show more
Investment focus
- Software, Information Technology, Health Care
- Funding Round, Seed, Series A
- France, United States, Switzerland
Portfolio highlights
- Dfns — Supercharge your platform with keyless custody as a service. One API to generate secure wallets, manage your crypto, sign transactions, set up business rules, monitor security, and more.
- Biolevate — Accelerating Therapeutic Innovation: AI-Enhanced Workflow Automation
- Orakl Oncology — Cultivated with love by the Orakl team.
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Funding Round, Series A
- United Kingdom, United States
Portfolio highlights
- Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
- Antiverse — Designing biologics for 100 challenging targets
- iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
We help founders build enduring companies.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Series A, Series B, Series C
- China, United States, Hong Kong
Portfolio highlights
- Mocaverse — Mocaverse is the Animoca Brands membership NFT collection of 8,888 unique beings: The Mocas. Join the Mocas in the realms to Learn, Play, Do Good, and Build together as we champion our Web3 values!
- XellSmart — Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.
- Aden Energy — Aden Energy is the new energy and energy technology business of Aden Group.Aden Energies helps enterprises, districts, and cities negotiate energy transitions and meet the essential problems of portfolio decarbonization.
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Show more
Investment focus
- Software, Information Technology, Biotechnology
- Seed, Series A, Funding Round
- Germany, Switzerland, United States
Portfolio highlights
- IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
- Sedivention — Sedivention is a medical technology startup that enables a one-time, interventional, and minimally invasive therapy for obesity. The company is developing a cryo catheter that ablates the gastric branches of the vagus nerve within minutes. As a one-time, minimally invasive procedure, the procedure can be performed in an outpatient setting, similarto a gastroscopy.
- SRTD Biotech — SRTD Biotech is an RNA-based biotechnology company that focuses on oncology, infectious, and genetic disorders.
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
- Software, Biotechnology, Health Care
- Series A, Series B, Series C
- United States, United Kingdom, Israel
Portfolio highlights
- Glooko — Glooko's digital health and connected care solutions improve health outcomes for people with diabetes and related chronic conditions.
- Nivoda — Nivoda provides jewellery businesses with a simple solution to strengthen profits, increase efficiency and accelerate growth with its B2B diamond marketplace. Designed to save you time and money whilst giving you access to the world’s diamond supply at the best prices with zero inventory risk, Nivoda is trusted by thousands of retailers all overthe globe.
- Enterpret — All customer feedback categorized automatically, combined with advanced analytics capabilities that ensure no customer pain goes unnoticed.
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Funding Round, Series A
- United States, Canada
Portfolio highlights
- KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
- Tolerance Bio — Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergi
- Vittoria Biotherapeutics — Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Germany, Belgium
Portfolio highlights
- Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
- Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
- Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Seed, Series B
- United States, United Kingdom, Canada
Portfolio highlights
- Shiru — Discover Shiru. We are an Ingredient Company that Identifies and Creates Functional Ingredients for the Plant-Based Industry.
- Enveda Biosciences — Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California.
- Physical Intelligence — Physical Intelligence is bringing general-purpose AI into the physical world.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- China, United States, Hong Kong
Portfolio highlights
- Syneron — Syneron was founded by Sinovation Ventures and is dedicated to using artificial intelligence and biotechnology to address two significant global challenges: the efficient development of novel biological therapies and the low-carbon manufacture of biochemicals.
- Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
- Chimagen Biosciences — Chimagen Biosciences is a company that is creating a novel class of multi-functional monoclonal antibodies for cancer therapy.
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, Switzerland
Portfolio highlights
- Enara Bio — Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-relatedDNA sequences.
- TRex Bio — TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
GV supports innovative founders moving the world forward.
Show more
Investment focus
- Software, Health Care, Biotechnology
- Series A, Series B, Seed
- United States, United Kingdom, Switzerland
Portfolio highlights
- Roboflow — With just a few dozen example images, you can train a working, state-of-the-art computer vision model in less than 24 hours
- Synapticure — The era of personalized care is finally coming to ALS. Synapticure will give all ALS patients access to the best care while fueling the advancement of personalized treatments for every type of ALS.
- Rox — Transform your sales process with Rox. Leverage AI agents to boost productivity, gain actionable insights, and close deals faster.
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more
Investment focus
- Biotechnology, Health Care, Pharmaceutical
- Series B, Series A, Series C
- United States, France, Switzerland
Portfolio highlights
- Axonis Therapeutics — AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.
- Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
- Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
- Software, Information Technology, Internet
- Series A, Seed, Series B
- United States, United Kingdom, Brazil
Portfolio highlights
- xAI — XAI is an AI company that develops a platform to accelerate human scientific discovery. The company primarily focuses on developing advanced AI systems that are truthful, competent, and maximally beneficial for all of humanity. Its mission is to understand the true nature of the universe.
- HappyRobot — Happyrobot is the AI that extracts quantitative data from geospatial imagery with English queries
- Sinatra — Sinatra's AI copilot for e-commerce assists medium and big firms in streamlining operations. through process automation, real-time anomaly detection and analysis, auditing of sales pipelines to increase profitability and cut expenses, and platform integration.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Funding Round
- United States, United Kingdom, Israel
Portfolio highlights
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
- EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.
We are deep tech venture capital.
Show more
Investment focus
- Software, Artificial Intelligence, Health Care
- Seed, Series A, Series B
- United States, Canada, United Kingdom
Portfolio highlights
- Q-CTRL — Infrastructure software to power the quantum future
- Radiant — Clean. Portable. Safe. Energy
- Reality Defender — Reality Defender is deepfake detection done right. With billions of visual and audio assets indexed, we offer the most robust deepfake detection available.
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Germany, Canada
Portfolio highlights
- Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
- BillionToOne — We are a team at the forefront of disease detection focused on moving Prenatal Screening and Liquid Biopsy forward.
- Waypoint Bio — Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, The Netherlands, Switzerland
Portfolio highlights
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
- PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
- ATB Therapeutics — ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, United Kingdom, Canada
Portfolio highlights
- Nomic — Nomic develops a proteomic technology platform designed to understand, detect, and treat diseases with DNA nanotechnology. NPlex's platform and research provides cost-effective measurement of protein data with sample, fits seamlessly within industry cytometers for high-throughput analysis, and development of custom protein panels.It allowsnanotechnology developers and businesses to bring improvement in existing instrument, workflow, and bring automation in the system.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Series A, Series B
- United Kingdom, United States, Philippines
Portfolio highlights
- Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
- Evoralis — Utilise Our Innovative Enzymes to Efficiently Recycle Plastics Into High-Quality Raw Materials
- Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. They manage over $4 billion in assets and focus on building companies with groundbreaking scientific platforms that have the potential to deliver significant new therapies for unmet medical needs. TCG takes a long-term approach, aimingto develop companies capable of generating multiple product opportunities rather than focusing on quick exits.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States
Portfolio highlights
- Nura Bio — Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders.
- Circle Pharma — Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.
- NGM Biopharmaceuticals — Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients.
Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Series A, Series B, Funding Round
- France, United States, Germany
Portfolio highlights
- Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
- Siit — Siit is a modern IT service management platform. Conversational, integrated and AI-powered service desk for IT and internal operation teams. Simplify internal operations today!
- Sequentia Biotech — Sequentia Biotech is a bioinformatics company that offers services for healthcare, pharma, agriculture, industry and environment.
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United States, Israel, Germany
Portfolio highlights
- Marigold Health — Marigold Health is an anonymous social network where people with mental health and substance use conditions support each other.
- March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
- Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Funding Round
- United States, Canada
Portfolio highlights
- Endogenex — DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
- Synaptrix — Synaptrix is a medical device start-up company dedicated to developing and commercializing drug-free pain management solutions for postoperative joint surgery patients. The proprietary NOVABLOC system is a procedure-based solution that delivers a novel type of electrical stimulation. Human feasibili
- AtaCor Medical — AtaCor Medical - Designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, France, China
Portfolio highlights
- Idrx — IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies.
- TMRW Life Sciences — TMRW helps patients and clinics safely store their eggs and embryos
- BridgeBio Oncology Therapeutics — BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.
Impacting the future of medicine.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Series C
- United States, United Kingdom, The Netherlands
Portfolio highlights
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
- SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.
- Navigator Medicines — Leading the advancement of biologics for targeted immune regulation & restoration.
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Funding Round
- United States, Israel, Canada
Portfolio highlights
- AmpUp — Commercial electric vehicle (EV) charging network solutions made simple for everyone. Easily manage and analyze EV charging data from a single dashboard.
- Air Company — We are a carbon utilization company working with industries to create planetary change, taking Earth's excess CO2 and converting it into carbon-negative alcohols and fuels.
- Nimbus Power Systems — Nimbus builds a cleaner world through design and integration of zero-emission fuel cell systems for heavy-duty markets.
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more
Investment focus
- Biotechnology, Software, Health Care
- Grant, Funding Round, Seed
- United Kingdom, United States, Japan
Portfolio highlights
- MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
- Biotangents — Biotangents develops veterinary diagnostic tests to detect infectious diseases in livestock (bovine viral diarrhoea (BVD), mastitis, bovine respiratory disease (BRD), brucellosis) using our highly adaptable molecular diagnostic technology, Moduleic Sensing.
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
With its purpose-driven culture and deep industry expertise, Frazier Healthcare is the preferred partner to profitable healthcare companies.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Post-IPO Equity
- United States, Canada, Ireland
Portfolio highlights
- Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
- New Amsterdam Pharma — We're advancing a new era of treatment for cardiovascular disease and other lipid-related conditions.
- Day One Biopharmaceuticals — Day One Biopharmaceuticals is a clinical-stage company dedicated to developing and commercializing innovative targeted therapies for patients of all ages.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Seed, Series A, Series B
- United Kingdom, United States, Finland
Portfolio highlights
- natcap — We support the world's leading companies to prioritise, measure and act on nature impacts, dependencies, risks and opportunities.
- FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
- Iota Sciences — Discover automated single-cell handling tools and related services to accelerate your route to breakthrough discoveries in cell biology
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series A, Funding Round
- United States, Sweden, France
Portfolio highlights
- Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
- Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
- SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.
Investors by industry
Biotech
Proptech
Gaming
FinTech
Health Care
Community
Google
Marketplace
Climate
Consumer
Artificial intelligence
Impact
Energy
Hardware
EdTech
Sustainability
Venture Capital
Clean Energy
B2B
Real Estate
Publishing
Payments
Big Data
Retail
Organic Food
Web3
Education
Finance
Food and Beverage
Video Games
Infrastructure
Financial Services
Photography
Beauty
Medical
Wellness
Social Media
Social Network
Android
Construction
Art
Local
Legal
Digital Media
Manufacturing
eSports
Sports
Music
Mobile
Internet
Enterprise Software
Franchise
Email
Travel
Mobile Advertising
Biotechnology
Recruiting
Hospitality
Fitness
Platforms
Cannabis
Medical Device
Social
Automotive
Crowdfunding
Wine And Spirits
CleanTech
Mobile Apps
Transportation
InsurTech
Enterprise
LGBT
Fashion
Oil and Gas
Life Science
Film
Theatre
Non Profit
Renewable Energy
SaaS
Sporting Goods
Social Impact
Restaurants
Software
Celebrity
Cryptocurrency
Agriculture (agtech)
Media (entertainment)
Facebook
Blockchain
Investors by country
India
Germany
South Korea
United Kingdom
Australia
Canada
New Zealand
Ireland
United States
Qatar
Saudi Arabia
Spain
Sri Lanka
China
Middle East
Africa
Indonesia
Europe
Armenia
Singapore
Oceania
Brazil
Japan
South Africa
Vietnam
LATAM
Asia
Denmark
Costa Rica
Bermuda
Egypt
Croatia
Gibraltar
Algeria
Estonia
Ecuador
Greece
Chile
Bulgaria
Ethiopia
Hong Kong
Faroe Islands
France
Ghana
Czech Republic
Hungary
Georgia
Belgium
Finland
Bahrain
Belarus
Belize
Barbados
Lebanon
Mali
Puerto Rico
Tunisia
Uganda
Liberia
Sierra Leone
Senegal
San Marino
Uzbekistan
Seychelles
Togo
El Salvador
Rwanda
Russian Federation
Tanzania
Ukraine
Zimbabwe
Uruguay
Serbia
Taiwan
Venezuela
Tajikistan
Sweden
Turkey
Poland
Thailand
Zambia
Portugal
Slovenia
Dominican Republic
Azerbaijan
Iraq
Iceland
Bahamas
Namibia
Nigeria
United Arab Emirates
Jamaica
Honduras
Malta
Bolivia
Isle of Man
Luxembourg
Liechtenstein
Albania
Pakistan
Malaysia
Italy
Panama
Myanmar
Mauritius
Bangladesh
Argentina
Grenada
Jordan
Romania
Nicaragua
Philippines
Lithuania
Israel
Jersey
Norway
Morocco
Mexico
Peru
Kuwait
Kenya
Kazakhstan
Cayman Islands
Cambodia
Cyprus
Latvia
Oman
Cameroon
Austria
Switzerland
Guatemala
Colombia
Marshall Islands
Investors in Biotechnology by country
Kenya
Sweden
United States
Brazil
Finland
Poland
Denmark
Canada
Indonesia
South Africa
Turkey
LATAM
Switzerland
United Kingdom
Isle of Man
Hong Kong
Japan
Asia
Italy
Kazakhstan
Australia
Ireland
Africa
Austria
Oceania
China
Georgia
Hungary
Taiwan
Egypt
Singapore
Spain
Belgium
France
Europe
United Arab Emirates
Norway
Israel
Portugal
Middle East
Argentina
Chile
Mexico
New Zealand
Estonia
Germany
South Korea
Thailand
Latvia
Lithuania
Russian Federation
Uruguay
Iceland
India
Angel investors in Biotechnology by country
VC (Venture Capital) Funds in Biotechnology by country
United Arab Emirates
Kenya
Portugal
Middle East
Sweden
United States
Brazil
Finland
Poland
Canada
Indonesia
South Africa
Denmark
Switzerland
United Kingdom
Germany
Turkey
Hong Kong
Japan
Asia
Mexico
Australia
India
Ireland
Africa
Georgia
Italy
Taiwan
Hungary
Austria
Oceania
China
Egypt
Iceland
Singapore
Belgium
Israel
France
Europe
Latvia
Argentina
Norway
Uruguay
Russian Federation
South Korea
Chile
Estonia
Spain
New Zealand
LATAM
Lithuania
Thailand